Wellness and the Role of Comorbidities in Multiple Sclerosis

Moss, Brandon P; Rensel, Mary; Hersh, Carrie M.

doi:10.1007/s13311-017-0563-6

Cited by 54 publications

(53 citation statements)

References 179 publications

(216 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…M ultiple sclerosis )MS( is a neurodegenerative, inflammatory, demyelinating disease of the central nervous system that has an increasing incidence. [1][2] It is one of world's most common neurologic disorders with a prevalence of 30.1 cases affected per 100 000 population worldwide. 3 Epidemiological studies have shown that MS has a high prevalence on the Arabian Gulf region.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Awareness of patients with multiple sclerosis in Saudi Arabia regarding the relationship between smoking and multiple sclerosis

Bashamakh

Alsharif

Wayyani

et al. 2019

NSJ

View full text Add to dashboard Cite

Objectives: To assess the awareness of patients with multiple sclerosis about the relationship between smoking and multiple sclerosis in Saudi Arabia. Methods: A descriptive cross-sectional study was carried out in 2018 for 162 patients who are attending a tertiary hospital in Jeddah, Kingdom of Saudi Arabia. Self-administered questionnaire and telephone-based interview were used to collect the data. The Analysis was carried out through a statistical package for the social sciences)SPSS(software version 21 by using chi-square. Results: A total of 162 patients responded to the questionnaire)response rate, 58.1%(. Among the respondents, 56 were current smokers, and 41 of them were males. Thirty-nine patients had a previous cessation attempt, and in 64.1% of the cases, it was mainly a self-made decision. Doctors counseled only 52.7% of the active smokers regarding the effect of smoking on the progression of their disease. Conclusion: Results indicate that there a is low level of awareness regarding the risk of smoking on multiple sclerosis. Therefore, educational programs and campaigns would be beneficial to fulfill the gap. Moreover, Health institutions and health care workers should take this issue into account when counseling the patient.

show abstract

mentioning

confidence: 99%

“…5 The medical costs of MS care rank second after congestive heart failure, with an estimated cost of $8528 to $54,244 per patient per year. 1 Multiple sclerosis has 4 clinical categories: primary progressive MS )PPMS(, secondary progressive MS )SPMS(, relapsing-remitting MS )RRMS(, and progressive relapsing MS )PRMS(. Almost 85% of patients present with RRMS.…”

mentioning

confidence: 99%

Awareness of patients with multiple sclerosis in Saudi Arabia regarding the relationship between smoking and multiple sclerosis

Bashamakh

Alsharif

Wayyani

et al. 2019

NSJ

View full text Add to dashboard Cite

show abstract

“…Disease modifying therapies are the primary treatment approach. These are geared to reduce inflammatory disease activity and slow worsening disability (Moss, Rensel, & Hersh, 2017). In addition to conventional pharmacologic therapy, there is growing support for psychological intervention as well as interest in the use of lifestyle strategies (e.g., exercise, nutrition, smoking cessation).…”

Section: Incidence Prevalence and Course Of Msmentioning

confidence: 99%

“…In addition to conventional pharmacologic therapy, there is growing support for psychological intervention as well as interest in the use of lifestyle strategies (e.g., exercise, nutrition, smoking cessation). Complementary and alternative medicines to support wellness and mitigate disease-related complications in MS are also expanding (Moss, Rensel, & Hersh, 2017).…”

Section: Incidence Prevalence and Course Of Msmentioning

confidence: 99%

Working With Clients With Multiple Sclerosis

Werfel

Trettin²

2019

J Health Serv Psychol

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a complex, unpredictable, and chronic neurologic disorder that can affect numerous bodily systems and result in minimal symptoms or in significant disability. There is no known cause or cure. The role of the mental health professional has been well recognized in evidenced-based treatment of individuals living with MS. There is no definitive psychological theory or treatment. However, a multimodal approach that includes the management of stress, fatigue, pain, cognitive deficits, and psychological diagnoses is recommended. This approach also works toward increasing resilience and ability to self-manage symptoms, building a viable healthcare and wellness plan, and strengthening interpersonal relationships. Jasmine, a 35-year-old, married, black mother of two, asked her neurologist for a referral because of her struggles with increasing symptoms from relapsing-remitting multiple sclerosis (RRMS). She was initially diagnosed three years ago after several years of reported symptoms were ignored or misdiagnosed. Jasmine states that she wants to learn better ways to cope with MS. She describes balance issues, fatigue, pain, restless sleep, worry, and difficulty with concentration and memory. She appears anxious as she describes the struggles she has encountered in her position as an administrator. She feels overwhelmed and has lost self-confidence. She, however, reports having a supportive husband and manager. She also expresses guilt that she is not living up to the expectations as a wife and mother of two young children. Jasmine reports previously feeling relatively happy, optimistic, and social, but she now participates less in family, social, and church activities. Jasmine appears motivated and reports no prior mental health issues. She appears to be a good candidate for self-management interventions. Will stress, pain, and fatigue management strategies be a good starting point? Will success with these interventions decrease her anxiety and feelings of being overwhelmed? Will physical and cognitive accommodations be necessary in therapy? How do religious beliefs about illness and disability play a role in her coping with MS? How are anxiety and sleep disturbance affecting her MS symptoms and quality of life? Clinical Challenge Nature of Multiple Sclerosis Multiple sclerosis is a complex disease, and it can be difficult to diagnose and treat. It is not uncommon that

show abstract

“…McGinley and Rossman [14] offer a detailed discussion on pediatric MS and present a potential high efficacy treatment algorithm as a future direction to be studied in the pediatric population. Next, Moss et al [15] remind us that caring for the MS population also includes attending to their comorbidities and wellness, and offer useful recommendations for lifestyle modifications. Finally, Hartung [16] does a commendable job in describing the complex issues behind the pricing of MS therapies, particularly in the USA, the difficulties in determining the economic value of MS therapies, and covers potential solutions on this important topic.…”

mentioning

confidence: 99%

Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead

2017

View full text Add to dashboard Cite

One of the most challenging aspects of our role as guest editors for this special issue of Neurotherapeutics was deciding on the topics for review. Progress in the field of multiple sclerosis (MS) research has been substantial over the last several years. Whereas it may once have been possible to cover the entire field of MS in a single issue, that is certainly not the case today. Thus, rather than trying to be comprehensive, we selected topics that we felt would be the most high impact for our readers, allowing them to treat, educate, and advise patients with MS through the varied and complicated circumstances that they often present in the clinic. Additionally, despite much progress, several significant challenges in MS management remain, which we have attempted to highlight.The issue focuses on 4 main themes. First, several disease modifying therapies (DMTs) with complex safety profiles recently received regulatory approval, and we felt it important to cover these agents. Second, despite the rapid proliferation of DMTs over the last 10 years, situations sometimes arise in which no available treatment option is sufficiently potent for a patient. Further, unmet needs with respect to remyelination and neuroprotection, especially in progressive MS, are quite urgent. Thus, we wanted to acquaint our readers with the current pipeline of treatments and procedures that will hopefully be routinely available for patients with MS in the near future. Third, MS clinical trials are a constantly evolving subject, especially with respect to outcomes, which prompted us to review some of the newest concepts in clinical trial design. Finally, with so many DMTs available, the decision of which to use and when requires greater sophistication than ever before. Not only is the choice a delicate balance of safety, efficacy, and cost, but there are also special populations to consider, such as pregnant women and children. Therefore, we conclude with a series of articles addressing important treatment considerations.With respect to currently available therapies, ocrelizumab has generated significant excitement not only due to its potent efficacy in relapsing-remitting MS, but also as the first agent to receive approval for the treatment of primary progressive MS. Gelfand et al.[1] provide a comprehensive review of Bcell biology and its relationship to MS, as well as covering ocrelizumab, rituximab, and ofatumumab. Daclizumab is a recently approved agent that requires intensive safety monitoring, especially with respect to hepatotoxicity and cutaneous events. Baldassari and Rose [2] provide a thoughtful analysis of its place in the DMT landscape. Finally, Chaudhry et al. [3] review fingolimod and present a bridge into the pipeline section with a discussion of second-generation sphingosine-1-phosphate receptor modulators with greater receptor subtype specificity.Pipeline treatments include cladribine, which was rejected by the Food and Drug Administration and the European Medicines Agency several years ago but recently received approval ...

show abstract

Wellness and the Role of Comorbidities in Multiple Sclerosis

Cited by 54 publications

References 179 publications

Awareness of patients with multiple sclerosis in Saudi Arabia regarding the relationship between smoking and multiple sclerosis

Awareness of patients with multiple sclerosis in Saudi Arabia regarding the relationship between smoking and multiple sclerosis

Working With Clients With Multiple Sclerosis

Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead

Contact Info

Product

Resources

About